Santalum album mouthwash - Santalis

Drug Profile

Santalum album mouthwash - Santalis

Alternative Names: Albuterpenoid - Santalis; East Indian Sandalwood Oil (EISO) mouth rinse - Santalis; SAN-005

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Santalis Pharmaceuticals
  • Class Anti-infectives; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Stomatitis

Most Recent Events

  • 09 Sep 2016 Santalis Pharmaceuticals has patent protection for santalum album mouthwash in Japan
  • 17 Mar 2015 Clinical trials in Stomatitis in USA (Buccal)
  • 17 Mar 2015 Santalis Pharmaceuticals plans a phase II trial for Stomatitis in USA (NCT02399228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top